Condition
Sinonasal Undifferentiated Carcinoma
Total Trials
5
Recruiting
3
Active
4
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 5 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
5Total
Not Applicable (1)
P 1 (1)
P 2 (3)
Trial Status
Recruiting3
Unknown1
Active Not Recruiting1
Clinical Trials (5)
Showing 5 of 5 trials
NCT06814496Phase 1Recruiting
Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors
NCT05925491Phase 2RecruitingPrimary
Pembrolizumab in Locally Advanced Sinonasal Carcinoma
NCT00707473Phase 2Active Not Recruiting
Docetaxel, Cisplatin and Fluorouracil in Treating Patients With Previously Untreated Stage II-IV Nasal Cavity and Paranasal Sinus Cancer
NCT06940180Phase 2Recruiting
Toripalimab With Chemotherapy for Sinus Cancer
NCT01586767Not ApplicableUnknown
Intensity-Modulated or Proton Radiation Therapy for Sinonasal Malignancy
Showing all 5 trials